Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF):Biology and Clinical Status

  • Ann Jakubowski

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of the naturally-occurring glycoprotein hormones which regulate hematopoietic precursors in the bone marrow and peripheral blood effector cells. It is one of the original ‘colony-stimulating factors’ whose name is derived from its major target cell lineages (Table 1). Although it was initially purified from media used to culture a monoclonal T-lymphoblastoid cell line (Mo) [50], it has also since been found to be produced by a variety of cell types including macrophages, endothelial cells and certain mesenchymal cells. There are no basal serum levels of GM-CSF in normal adults, but its production is readily inducible by many of the mediators of inflammation. The gene for GM-CSF was sequenced and cloned in 1985 [26,151] and has been expressed in E.

Keywords

Acute Myeloid Leukemia Aplastic Anemia Acute Myelogenous Leukemia Autologous Bone Marrow Transplantation Hematopoietic Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 551–557.PubMedCrossRefGoogle Scholar
  2. 2.
    Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705–713.PubMedGoogle Scholar
  3. 3.
    Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593–598.PubMedCrossRefGoogle Scholar
  4. 4.
    Archimbaud E, Fenaux P, Reiffers J, et al. Granulocytemacrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993; 7: 372–377.PubMedGoogle Scholar
  5. 5.
    Arnout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78: 597–601.CrossRefGoogle Scholar
  6. 6.
    Bajorin D, Nichols CR, Schmoll H-J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamidebased chemotherapy for patients with advanced or relapsed germ cell tumors: A randomized trial. J Clin Oncol 1995; 13:79–86.PubMedGoogle Scholar
  7. 7.
    Baldwin GC, Gasson JC, Kaufman SE, et al. Nonhematopoietic tumor cells express functional CSF receptors. Blood 1989; 73: 1033–1037.PubMedGoogle Scholar
  8. 8.
    Baldwin GC, Gasson JC, Quan SG, et al. Granulocytemacrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1988; 856: 2763–2766.CrossRefGoogle Scholar
  9. 9.
    Baldwin GC, Golde DW, Widhopf GF, et al. Identification and characterization of a low-affinity granulocyte-macrophage colony-stimulating factor receptor on primary and cultured human melanoma cells. Blood 1991; 78: 609–615.PubMedGoogle Scholar
  10. 10.
    Barlogie B, Jagannath S, Dixon DO, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677–680.PubMedGoogle Scholar
  11. 11.
    Berdel WE, Danhauser-Riedel S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin- 3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 80–83.PubMedGoogle Scholar
  12. 12.
    Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700–711.PubMedGoogle Scholar
  13. 13.
    Bishop MR, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocytemacrophage colony-stimulating factor on the autograft. Blood 1994; 83:610–616.PubMedGoogle Scholar
  14. 14.
    Blazar BR, Kersey JH, McGlave PB, et al. In vivo administration of recombinant human granulocyte/ macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73:849–857.PubMedGoogle Scholar
  15. 15.
    Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after highdose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–876.PubMedCrossRefGoogle Scholar
  16. 16.
    Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colonystimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–1197.PubMedGoogle Scholar
  17. 17.
    Budel LM, Elbaz O, Hoogerbrugge H, et al. Common binding structure for granulocyte macrophage colonystimulating factor and interleukin-3 on human acute myeloid leukemia cells and monocytes. Blood 1990; 75: 1439–1445.PubMedGoogle Scholar
  18. 18.
    Budel LM, Touw IP, Delwel R, Clark SC, Lowenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship the proliferative response. Blood 1989; 74:565–571.PubMedGoogle Scholar
  19. 19.
    Bukowski RM, Murthy S, McLain D, et al. Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer. Clinical and immunologic effects. J Immunother 1993; 13: 267–274.CrossRefGoogle Scholar
  20. 20.
    Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III radomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632–1641.PubMedGoogle Scholar
  21. 21.
    Burgess AW, Begley CG, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocyte macrophage colony stimulating factor. Blood 1987; 69:43–51.PubMedGoogle Scholar
  22. 22.
    Calderwood S, Rumeyer F, Freedman MH. GM-CSF in childhood acute lymphoblastic leukemia: Randomized double blind trial during intensification phase. Blood 1992; 80(supplement): 288a.Google Scholar
  23. 23.
    Cannistra SA, DiCarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colonystimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5:230–238.PubMedGoogle Scholar
  24. 24.
    Cannistra SA, Groshek P, Garlick R, et al. Regulation of surface expression of the granulocyte/macrophage colony stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci USA 1990; 87: 93–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Cannistra SA, Vallenga E, Groshek P, et al. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988; 71:672–676.PubMedGoogle Scholar
  26. 26.
    Cantrell MA, Anderson D, Ceretti DP, et al. Cloning sequence and expression of human granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 1985;73:6250–6254.CrossRefGoogle Scholar
  27. 27.
    Cebon J, Dempsey P, Fox R, et al. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood 1988; 72: 1340–1347.PubMedGoogle Scholar
  28. 28.
    Champlin RE, Nimer SD, Ireland P, et al. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 73: 694–699.PubMedGoogle Scholar
  29. 29.
    deVries EGE, Biesma B, Willemse PHB, et al. A doubleblind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 116–122.PubMedGoogle Scholar
  30. 30.
    DeWitte T, Gratwohl A, VanDer Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359–1365.PubMedGoogle Scholar
  31. 31.
    Dedhar S, Gaboury L, Galloway P, Eaves C. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhematopoietic origin. Proc Natl Acad Sci USA 1988; 85:9253–9257.PubMedCrossRefGoogle Scholar
  32. 32.
    Devereux S, Bull HA, Campos-Costa D, et al. Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to edothelium: in-vitro and in-vivo studies in man. Br J Haemotol 1989; 71: 323–330.CrossRefGoogle Scholar
  33. 33.
    Devereux S, Linch DC, Campos-Costa D, et al. Transient leucopenia induced by granulocyte macrophage colony stimulating factor (Letter). Lancet 1987; ii: 1523–1524.CrossRefGoogle Scholar
  34. 34.
    DiPersio J, Billing P, Kaufman S, et al. Characterization of the human granulocyte-macrophage colony-stimulating factor receptor. J Biol Chem 1988; 263: 1834–1841.PubMedGoogle Scholar
  35. 35.
    Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of myelodysplastic syndromes with human granulocyte-macrophage colony-stimulating factor (GMCSF) or GM-CSF combined with low-dose cytosine arabinoside. Eur J Haematol 1992; 49: 138–142.PubMedCrossRefGoogle Scholar
  36. 36.
    Edmonson JH, Colon-Otero G, Long HG, et al. Granulocyte- macrophage colony-stimulating factor (GM-CSF) permits escalation of carboplatin (CBDCA) doses. Proc Am Soc Clin Oncol 1990; 9: 330a.Google Scholar
  37. 37.
    Edmonson JH, Hartmann LC, Long H J, et al. Granulocytemacrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 1992; 70:2529–2539.PubMedCrossRefGoogle Scholar
  38. 38.
    Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036–3044.PubMedGoogle Scholar
  39. 39.
    Elliott MJ, Vadas MA, Eglinton JM, et al. Recombinant human interleukin-3 and granulocyte-macrophage colony- stimulating factor show common biological effects and binding characteristics on human monocytes. Blood 1989; 74:2349–2359.PubMedGoogle Scholar
  40. 40.
    Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925–929.PubMedGoogle Scholar
  41. 41.
    Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocytemacrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–2255.PubMedGoogle Scholar
  42. 42.
    Estey EH, Dixon D, Kantarjian HM, et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75: 1766–1769PubMedGoogle Scholar
  43. 43.
    Foulke RS, Marshall MH, Trotta PP, vonHoff DD. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264–6267.PubMedGoogle Scholar
  44. 44.
    Freedman MJ, Grunberger T, Correa P, et al. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood 1993; 81: 3068–3075.PubMedGoogle Scholar
  45. 45.
    Ganser A, Ottman OG, Erdmann H, et al. The effect of recombinant human granulocyte-macrophage colonystimulating factor on neutropenia and related morbidity in chronic severe neutropenia. Ann Intern Med 1989; 111: 887–892.PubMedGoogle Scholar
  46. 47.
    Ganser A, Volkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-A phase I/II trial. Blood 1989; 73:31–37.PubMedGoogle Scholar
  47. 48.
    Gasson JC. Hematopoietic growth factor receptors on solid tumors. Hematopoietic Therapy Index & Reviews 1993; 11(1) 1.Google Scholar
  48. 49.
    Gasson JC, Kaufman SE, Weisbart RH, Tomonaga M, Golde DW. High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci USA 1986; 83: 669–673.PubMedCrossRefGoogle Scholar
  49. 50.
    Gasson JC, Weisbart RH, Kaufman SE, et al. Purified human granulocyte-macrophage colony-stimulating factor: Direct action on neutrophils. Science 1984; 226: 1339–1342.PubMedCrossRefGoogle Scholar
  50. 51.
    Gasson JC, Weissbart RH, Kaufman SE, et al. Purified human granulocyte-macrophage colony-stimulating factor: Direct action of neutrophils. Science 1984; 226: 1339–1342.PubMedCrossRefGoogle Scholar
  51. 52.
    Gearing DP, King JA, Gough NM, Nicola NA. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO Journal 1989; 8: 3667–3676.PubMedGoogle Scholar
  52. 53.
    Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colonystimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 1993;82:2329–2339.PubMedGoogle Scholar
  53. 54.
    Gerhartz HH, Marcus R, Delmer A, et al. A randomised phase II study of low-dose cytosine arabinoside plus GMCSF in MDS with a high risk of developing leukemia. Leukemia 1994; 8: 16–23.PubMedGoogle Scholar
  54. 55.
    Gesner T, Mufson RA, Turner KJ, Clark SC. Identification through chemical cross-linking of distinct granulocytemacrophage colony-stimulating factor and interleukin-3 receptors on myeloid leukemic cells, KG-1. Blood 1989; 74:2652–2656.PubMedGoogle Scholar
  55. 56.
    Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lymphoma. J Clin Oncol 1990; 8: 768–778.PubMedGoogle Scholar
  56. 57.
    Gianni AM, Bregni M, Stern AC, et al. Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580–584.CrossRefGoogle Scholar
  57. 58.
    Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin’s lymphoma: A double-blind placebo-controlled trial. Blood 1992; 80: 1149–1157.PubMedGoogle Scholar
  58. 59.
    Gough NM, Gearing DP, Nicola NA, et al. Localization of the human GM-CSF receptor gene to the X-Y pseudoautosomal region. Nature 1990; 345: 734–736.PubMedCrossRefGoogle Scholar
  59. 60.
    Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocytemacrophage colony-stimulating fetor. Science 1986; 232: 506–508.PubMedCrossRefGoogle Scholar
  60. 61.
    Gradishar W, LeBeau MM, O’Laughlin R, et al. Clinical and cytogenetic responses to GM-CSF in therapy-related myelodysplastic syndrome. Blood 1992; 80: 2463–2470.PubMedGoogle Scholar
  61. 62.
    Grem JL, McAtee N, Murphy RF, et al. Phase I and pharmacokinetic study of recombinant human granulocyte- macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994;12:560–568.PubMedGoogle Scholar
  62. 63.
    Griffin JD, Spertini O, Ernst TJ, et al. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol 1990; 145: 576–584.PubMedGoogle Scholar
  63. 64.
    Griffin JD, Young D, Herrmann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblasts leukemia. Blood 1986; 67: 1448–1453.PubMedGoogle Scholar
  64. 65.
    Groopman JE, Mitsuyasu RT, DeLeo MJ, et al. Effect of recombinant human granulocyte-macrophage colonystimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 593–598.PubMedCrossRefGoogle Scholar
  65. 66.
    Guinan EC, Sieff CA, Oette DH, et al. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood 1990;76:1077–1082.PubMedGoogle Scholar
  66. 67.
    Gulati S, Bennett CL. Granulocyte-macrophage colonystimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin’s disease. Ann Int Med 1992; 116: 177–182.PubMedGoogle Scholar
  67. 68.
    Haas R, Ho AD, Bredthauer U, et al. Successful autologous transplanation of blood stem cells mobilized with recombinant human granulocyte-macrophage colonystimulating factor. Exp Hematol 1990; 18: 94–98.PubMedGoogle Scholar
  68. 69.
    Handman E, Burgess AW. Stimulation by granulocytemacrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979; 120: 1134–1137.Google Scholar
  69. 70.
    Harakati MS, Al-Momen A, Ajarim DS, et al. Granulocyte- macrophage colony-stimulating factor (GM-CSF) in adult patients with acute lymphoblastic leukemia treated with conventional chemotherapy. Blood 1994; 84(supplement): 582a.Google Scholar
  70. 71.
    Hayashida K, Kitamura T, Gorman DM, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GMCSF): Reconsitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990; 87: 9655–9659.PubMedCrossRefGoogle Scholar
  71. 72.
    Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a doubleblind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3–9.PubMedGoogle Scholar
  72. 73.
    Hermann F, Lindemann A, Klein H, et al. Effect of recombinant human granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989; 3: 335–338.Google Scholar
  73. 74.
    Herrmann F, Schulz G, Lindemann A, et al. Yeastexpressed granulocyte-macrophage colony-stimulating factor in cancer patients: A phase lb clinical study. Behring Inst Mitt 1988; 83: 107–118.PubMedGoogle Scholar
  74. 75.
    Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989; 7: 159–167.PubMedGoogle Scholar
  75. 76.
    Herrmann F, Wieser M, Kolbe K, et al. Effect of granulocyte- macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Amer J Med 1990; 88: 619–624.PubMedCrossRefGoogle Scholar
  76. 77.
    Ho AD, DelValle F, Engelhard M, et al. Mitoxantrone/ high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. Cancer 1990; 66:423–430.PubMedCrossRefGoogle Scholar
  77. 78.
    Hoekman K, Wagstaff J, vanGroeningen CJ, et al. Effects of recombinant human granulocyte-macrophage colonystimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991; 83: 1546–1553.PubMedCrossRefGoogle Scholar
  78. 79.
    Hovgaard DJ, Nissen NI. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin’s disease: A phase I/II study. J Clin Oncol 1992; 10:390–397.PubMedGoogle Scholar
  79. 80.
    Huebner K, Isobe M, Croce CM, et al. The human gene encoding GM-CSF is at 5q21-q32, the chromosome region deleted in the 5q- anomaly. Science 1985; 230: 1282–1285.PubMedCrossRefGoogle Scholar
  80. 81.
    Kanakura Y, Druker B, Cannistra SA, et al. Signal transduction of the human granulocyte-macrophage colonystimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood 1990; 76: 706–715.PubMedGoogle Scholar
  81. 82.
    Kantarjian HM, Estey EH, O’Brien S, et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colonystimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992; 79: 876–881.PubMedGoogle Scholar
  82. 83.
    Kehoe S, Poole CJ, Stanely A, et al. A phase I/II trial of recombinant human granulocyte-macrophage colonystimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer 1994; 69: 537–540.PubMedCrossRefGoogle Scholar
  83. 84.
    Krigel RL, Palackdharry CS, Padavic K, et al. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer. J Clin Oncol 1994; 12: 1251–1258.PubMedGoogle Scholar
  84. 85.
    Krown SE, Paredes J, Bundow D, et al. Interferon-a, zidovudine, and granulocyte-macrophage colony-stimulating factor: A phase I AIDS Clinical Trials Group study in patients with Kaposi’s sarcoma associated with AIDS.J Clin Oncol 1992; 10: 1344–1351.PubMedGoogle Scholar
  85. 86.
    Lang RA, Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene (GMCSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51: 675–686.PubMedCrossRefGoogle Scholar
  86. 87.
    Lazarus HM, Andersen J, Chen MG, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow tramsplantation for relapsed non-Hodgkin’s lymphoma: Blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 1991; 78: 830–837.PubMedGoogle Scholar
  87. 88.
    LeBeau MM, Epstein ND, O’Brien SJ, et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci USA 1987; 84: 5913–5917.PubMedCrossRefGoogle Scholar
  88. 89.
    Levine JD, Alan JD, Tessitore JH, et al. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood 1991; 78: 3148–3154.PubMedGoogle Scholar
  89. 90.
    Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocytemacrophage colony-stimulating factor in patients with advanced malignancy. Ann Int Med 1989; 110: 357–364.PubMedGoogle Scholar
  90. 91.
    Lieschke GJ, Maher D, O’Connor M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990; 50:606–614.PubMedGoogle Scholar
  91. 92.
    Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188–2195.PubMedGoogle Scholar
  92. 93.
    Logothetis CJ, Dexeus FH, Sella A, et al. Escalated therapy for refractory urothelial tumors: Methotrexatevinblastine- doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colonystimulating factor. J Natl Cancer Inst 1990; 82: 667–672.PubMedCrossRefGoogle Scholar
  93. 94.
    Lopez AF, Williamson J, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression and survival. J Clin Invest 1986; 78: 1220–1228.PubMedCrossRefGoogle Scholar
  94. 95.
    Luikart SD, MacDonald M, Huzar D, et al. Ability of daily or twice daily granulocyte-macrophage colony stimulating factor (GM-CSF) to support dose escalation of etoposide and carboplatin in extensive small cell lung cancer. Proc Am Soc Clin Oncol 1992; 10: 242a.Google Scholar
  95. 96.
    McClay EF, Braly PD, Kirmani S, et al. A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies. Cancer 1994; 74: 664–669.PubMedCrossRefGoogle Scholar
  96. 97.
    Merlano M, Benasso M, Cavallari M, et al. Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. Am J Clin Oncol 1994; 17:494–497.PubMedCrossRefGoogle Scholar
  97. 98.
    Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocytemacrophage colony stimulating factor. Blood 1986; 67: 37–45.PubMedGoogle Scholar
  98. 99.
    Mitsuyasu R, Levine J, Miles SA, et al. Effects of long term subcutaneous (SC) administration of recombinant granulocyte-macrophage colony-stimulating factor in patients with HIV-related leukopenia. Blood 1988; 72: 1297a.Google Scholar
  99. 100.
    Moore JDF, Pazdur R. Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte- macrophage colony-stimulating factor. Am J Clin Oncol 1992; 15:464–466.PubMedCrossRefGoogle Scholar
  100. 101.
    Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced transitional cell carcinoma. J Urol 1993; 150: 1131–1134.PubMedGoogle Scholar
  101. 102.
    Nemunaitis J, Anasetti C, Storb R, et al. Phase II trial of recombinant human granulocyte-macrophage colonystimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992;79:2572–2577.PubMedGoogle Scholar
  102. 103.
    Nemunaitis J, Buckner CD, Appelbaum FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77: 2065–2071.PubMedGoogle Scholar
  103. 104.
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Eng J Med 1991; 324: 1773–1778.CrossRefGoogle Scholar
  104. 105.
    Nemunaitis J, Singer J, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–253.PubMedGoogle Scholar
  105. 106.
    Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–836.PubMedGoogle Scholar
  106. 107.
    Nissen C, Tichelli A, Gratwohl A, et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 1988; 72: 2045–2047.PubMedGoogle Scholar
  107. 108.
    O’Day SJ, Rabinowe SN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte- macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma in first remission. Blood 1994; 83:2707–2714.PubMedGoogle Scholar
  108. 109.
    O’Dwyer PJ, LaCreta FP, Schilder R, et al. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 1352–1358.PubMedGoogle Scholar
  109. 110.
    O’Reilly SE, Gelmon KA, Onetto N, et al. Phase I trial of recombinant human granulocyte-macrophage colonystimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol 1993; 11: 2411–2416.PubMedGoogle Scholar
  110. 111.
    Onetto-Pothier N, Aumont N, Haman A, et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990; 75: 59–66.PubMedGoogle Scholar
  111. 112.
    Passos-Coelho JL, Ross AA, Moss TJ, et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1995; 85: 1138–1143.PubMedGoogle Scholar
  112. 113.
    Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719.PubMedGoogle Scholar
  113. 114.
    Peters WP, Shogan J, Shpall EJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor produces fever. Lancet 1988; i: 950.CrossRefGoogle Scholar
  114. 115.
    Peters WP, Stuart A, Affronti ML, et al. Neutrophil migration is defective during recombinant human granulocyte- macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988; 72: 1310–1315.PubMedGoogle Scholar
  115. 116.
    Pettenati MJ, LeBeau MM, Lemons RS, et al. Assignment of CSF-1 to 5q33.1: Evidence for the clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders. Proc Natl Acad Sci USA 1987; 84: 2970–2974.PubMedCrossRefGoogle Scholar
  116. 117.
    Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990;76:463–472.PubMedGoogle Scholar
  117. 118.
    Poplin E, Smith H, Behrens B, et al. SWOG 8825: Melphalan GM-CSF: A phase I study. Gynecol Oncol 1992;44:66–70.PubMedCrossRefGoogle Scholar
  118. 119.
    Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–1420.PubMedCrossRefGoogle Scholar
  119. 120.
    Rabinowe SN, Neuberg D, Beirman PJ, et al. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation from lymphoid malignancies. Blood 1993; 81: 1903–1908.PubMedGoogle Scholar
  120. 121.
    Reed E, Janik J, Bookman MA, et al. High-dose carboplatin and recombinant granulocyte-macrophage colonystimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993; 11: 2118–2126.PubMedGoogle Scholar
  121. 122.
    Rifkin RM, Hersh EM, Hultquist KN, et al. Therapy of the myelodysplastic syndrome (MDS) with subcutaneously (SC) administered recombinant human granulocytemacrophage colony-stimulating factor. Proc Am Soc Clin Oncol 1989; 8: 178a.Google Scholar
  122. 123.
    Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605–2610.PubMedGoogle Scholar
  123. 124.
    Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457–462.PubMedGoogle Scholar
  124. 125.
    Ruff MR, et al. Interferon gamma and granulocyte-macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small cell lung cancer cells. Proc Natl Acad Sci USA 1986; 83:6613–6617.PubMedCrossRefGoogle Scholar
  125. 126.
    Rusthoven J, Levin L, Esienhauer E, et al. Two phase I studies of carboplatin dose escalation in chemotherapynaive ovarian cancer patients supported with granulocytemacrophage colony-stimulating factor. J Natl Cancer Inst 1991; 83: 1748–1753.PubMedCrossRefGoogle Scholar
  126. 127.
    Salmon SE, Liu R. Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 1989; 7: 1346–1350.PubMedGoogle Scholar
  127. 128.
    Schuster MW, Thompson JA, Larson R, et al. Randomized trial of subcutaneous granulocyte-macrophage colonystimulating factor (GM-CSF) versus observation in patients (pts) with myelodysplastic syndrome (MDS) or aplastic anemia (AA). Proc Amer Soc Clin Oncol 1990; 9: 793a.Google Scholar
  128. 129.
    Shaffer DW, Smith LS, Burris HA, et al. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res 1993; 53: 5929–5933.PubMedGoogle Scholar
  129. 130.
    Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colonystimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10:464–473.PubMedGoogle Scholar
  130. 131.
    Shepherd FA, Gross PE, Rusthoven J, Eisenhauer EA. Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1992; 84: 59–60.PubMedCrossRefGoogle Scholar
  131. 132.
    Sieff C, Emerson SG, Donahue RE, et al. Human recombinant granulocyte-macrophage colony stimulating factor: a multi-lineage hematopoietin. Science 1985; 230: 1171–1173.PubMedCrossRefGoogle Scholar
  132. 133.
    Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of highdose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905–1914.PubMedGoogle Scholar
  133. 134.
    Silberstein DS, Owen WF, Gasson JC, et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocytemacrophage colony-stimulating factor. J Immunol 1986; 137:3290–3294.PubMedGoogle Scholar
  134. 135.
    Smith T. Successful use of granulocyte-macrophage colony- stimulating factor in patients with acute lymphocytic leukemia. Am J Med 1990; 89: 384–384.PubMedCrossRefGoogle Scholar
  135. 136.
    Socinski MA, Cannistra SA, Sullivan R, et al. Human granulocyte-macrophage colony stimulating factor induces expression of the CD l i b surface adhesion molecule on granulocytes in vivo. Blood 1988; 72: 691–697.PubMedGoogle Scholar
  136. 137.
    Takai S, Yamada K, Hirayama N, et al. Mapping of the human gene encoding the mutual signaltransducing subunit (P-chain) of granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) receptor complexes to chromosome 22ql 13.1. Hum Genet 1994; 93: 198–200.PubMedGoogle Scholar
  137. 138.
    Socinski MA, Schnipper EA, et al. Granulocyte-macrophage colony-stimulating factor expands the circulating hemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–1198.PubMedCrossRefGoogle Scholar
  138. 139.
    Steis RG, VanderMolen LA, Longo DL, et al. Reombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase lb trial .J Natl Cancer Inst 1990; 82: 697–703.PubMedCrossRefGoogle Scholar
  139. 140.
    Steward WP, Scarffe JH, Dirix LY, et al. Granulocytemacrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. Br J Cancer 1990; 61: 749–754.PubMedCrossRefGoogle Scholar
  140. 141.
    Stone R, George S, Berg D, et al. GM-CSFV placebo during remission induction for patients >60 years old with de novo acute myeloid leukemia: CALGB study #8923. ProcAmer Soc Clin Oncol 1994; 13: 992a.Google Scholar
  141. 142.
    Sutherland GR, Baker E, Callen DF, et al. Interleukin-5 is at 5q31 and is deleted in the 5q- syndrome. Blood 1988; 71: 1150–1152.PubMedGoogle Scholar
  142. 143.
    Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte- macrophage colony-stimulating factor in patients with myelodysplastic syndromes: Toxicity, pharmacokinetics, and hematologic effects. J Clin Oncol 1989; 7: 629–637.PubMedGoogle Scholar
  143. 144.
    Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266–1277.PubMedGoogle Scholar
  144. 145.
    Vadhan-Raj S, Buescher S, Broxmeyer HE, et al. Stimulation of myelopoiesis in patient with aplastic anemia by recombinant human granulocyte-macrophage colonystimulating factor. N Engl J Med 1988; 319: 1628–1634.PubMedCrossRefGoogle Scholar
  145. 146.
    Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1988; 317: 1545–1551.CrossRefGoogle Scholar
  146. 147.
    Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte- macrophage colony-stimulating factor is a neutrophil activator. Nature 1985; 314: 361–363.PubMedCrossRefGoogle Scholar
  147. 148.
    Weisbart RH, Golde DW, Gasson JC. Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-met-leu-phe receptors. J Immunol 1986; 137: 3584–3587.PubMedGoogle Scholar
  148. 149.
    Weiser WY, VanNiel A, Clark SC, et al. Recombinant human granulocyte-macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophage. J Exp Med 1987; 166: 1436–1446.PubMedCrossRefGoogle Scholar
  149. 150.
    Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–1063.PubMedGoogle Scholar
  150. 151.
    Wong GG, Witek JS, Temple PA, et al. Human GM-CSF molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228: 810–815.PubMedCrossRefGoogle Scholar
  151. 152.
    Yamashita Y, Nara N, Nobuo A. Antiproliferative and’ differentiative effect of granulocyte-macrophage colonystimulating factor on a variant human small cell lung cancer cell line. Cancer Res 1989; 49: 5334–5338.PubMedGoogle Scholar
  152. 153.
    Yarden Y, Escobedo JA, Kuang WJ. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986; 323:226–232.PubMedCrossRefGoogle Scholar
  153. 154.
    Yokota T, Arai N, DeVries Y et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hematopoietic cells. Immunol Rev 1988; 102: 137–187.PubMedCrossRefGoogle Scholar
  154. 155.
    Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblasts leukemia. Blood 1986; 68: 1178–1181.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Ann Jakubowski
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations